PCN111 Cost-Effectiveness Analysis of Ixazomib PLUS Lenalidomide-Dexamethasone Versus Daratumumab PLUS Lenalidomide-Dexamethasone in Multiple Myeloma Patients Received More THAN One PRIOR Treatment in China

Dec 1, 2020, 00:00
10.1016/j.jval.2020.08.248
https://www.valueinhealthjournal.com/article/S1098-3015(20)32504-3/fulltext
Title : PCN111 Cost-Effectiveness Analysis of Ixazomib PLUS Lenalidomide-Dexamethasone Versus Daratumumab PLUS Lenalidomide-Dexamethasone in Multiple Myeloma Patients Received More THAN One PRIOR Treatment in China
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32504-3&doi=10.1016/j.jval.2020.08.248
First page :
Section Title :
Open access? : No
Section Order : 10195
Categories :
Tags :
Regions :
ViH Article Tags :